Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 28, 2012; 18(24): 3089-3098
Published online Jun 28, 2012. doi: 10.3748/wjg.v18.i24.3089
Published online Jun 28, 2012. doi: 10.3748/wjg.v18.i24.3089
Table 1 Patient characteristics
Characteristics | G + E group (n = 31) | G group (n = 30) | P |
Age (yr) | 50.7 ± 1.8 | 46.9 ± 1.5 | 0.4161 |
Gender (male/female) | 4/27 | 8/22 | 0.2112 |
Hepatitis history (yes/no) | 5/26 | 6/24 | 0.7492 |
AFP ( ≤ 20 ng/mL/> 20 ng/mL) | 13/18 | 14/16 | 0.7992 |
Liver cirrhosis (Yes/no) | 10/21 | 7/23 | 0.5702 |
ALT ( ≤ 40 U/L/> 40 U/L) | 18/13 | 11/19 | 0.7952 |
Child-Pugh Score (A/B) | 2/29 | 2/28 | 1.0002 |
Tumor differentiation (I-II/III-IV) | 7/24 | 9/21 | 0.5702 |
Tumor size ( ≤ 5 cm/> 5 cm) | 8/23 | 7/23 | 1.0002 |
Tumor number (single/multiple) | 8/23 | 5/25 | 0.5342 |
Tumor encapsulation (complete/none) | 12/19 | 15/15 | 0.4442 |
Vascular invasion (no/yes) | 6/25 | 8/22 | 0.5542 |
Blood loss ( ≤ 200 mL/> 200 mL) | 1/30 | 4/26 | 0.1952 |
Anesthesia time ( ≤ 3 h/> 3 h) | 18/13 | 9/21 | 0.4262 |
VAS score | 3.58 ± 0.32 | 3.67 ± 0.38 | 0.8631 |
Dose of fentanyl (μg) | 0.30 ± 0.01 | 0.51 ± 0.01 | < 0.0011 |
Dose of morphine (mg) | 2.26 ± 0.08 | 95.30 ± 1.17 | < 0.0011 |
Dose of sevoflurane (mL) | 21.74 ± 0.70 | 37.90 ± 1.60 | < 0.0011 |
Table 2 T-helper 1, T-helper 2, T-helper 17 and regulatory T cell frequencies in patients
Variables | d0 (%) | d2 (%) | d7 (%) | P (d0/d2) | P (d0/d7) | P (d2/d7) |
Th1 | 7.21 ± 1.01 | 18.82 ± 1.93 | 13.40 ± 0.79 | < 0.001 | < 0.001 | 0.015 |
Th2 | 1.12 ± 0.09 | 3.32 ± 0.31 | 0.93 ± 0.10 | < 0.001 | 0.180 | < 0.001 |
Th17 | 2.57 ± 0.22 | 2.95 ± 0.26 | 1.23 ± 0.10 | 0.269 | < 0.001 | < 0.001 |
Treg | 6.02 ± 0.27 | 6.93 ± 0.38 | 5.45 ± 0.52 | 0.160 | 0.329 | 0.021 |
Th1/Th2 | 8.12 ± 1.24 | 8.50 ± 1.14 | 14.87 ± 1.26 | 0.823 | < 0.001 | < 0.001 |
Table 3 Comparison of T-helper 1, T-helper 2, T-helper 17, regulatory T cell frequencies and T-helper 1/T-helper 2 cell ratio between G + E and G anesthesia groups
Variables | G + E group (%) | G group (%) | P |
Th1 | |||
d0 | 7.44 ± 1.54 | 7.38 ± 1.35 | 0.87 |
d2 | 14.66 ± 1.96 | 20.42 ± 2.77 | 0.098 |
d7 | 16.57 ± 0.96 | 10.37 ± 0.84 | < 0.001 |
Th2 | |||
d0 | 1.08 ± 0.14 | 1.14 ± 0.12 | 0.745 |
d2 | 2.64 ± 0.30 | 3.98 ± 0.49 | 0.028 |
d7 | 0.73 ± 0.07 | 1.14 ± 0.17 | 0.231 |
Th17 | |||
d0 | 2.80 ± 0.26 | 2.65 ± 0.36 | 0.424 |
d2 | 2.56 ± 0.30 | 3.01 ± 0.38 | 0.374 |
d7 | 1.08 ± 0.10 | 1.45 ± 0.15 | 0.047 |
Treg | |||
d0 | 5.44 ± 0.26 | 6.62 ± 0.45 | 0.372 |
d2 | 7.42 ± 0.60 | 6.43 ± 0.46 | 0.194 |
d7 | 4.51 ± 0.56 | 6.19 ± 0.80 | 0.003 |
Th1/Th2 ratio | |||
d0 | 8.63 ± 1.76 | 7.62 ± 1.32 | 0.688 |
d2 | 9.67 ± 1.94 | 7.40 ± 1.26 | 0.253 |
d7 | 14.64 ± 0.56 | 6.03 ± 0.83 | < 0.001 |
Table 4 Comparison of interferon-γ, interleukin-4, interleukin-17, FoxP3 mRNA levels and interferon-γ/interleukin-4 mRNA ratio between G + E and G groups
Variables | G + E group (×105) | G group (×105) | P |
IFN-γ | |||
d0 | 21.84 ± 2.99 | 16.49 ± 0.84 | 0.585 |
d2 | 50.91 ± 1.46 | 62.87 ± 2.71 | 0.096 |
d7 | 41.05 ± 1.05 | 29.36 ± 0.73 | 0.029 |
IL-4 | |||
d0 | 47.12 ± 28.65 | 59.97 ± 15.17 | 0.651 |
d2 | 66.63 ± 18.45 | 110.12 ± 24.11 | < 0.001 |
d7 | 31.80 ± 14.59 | 58.21 ± 5.74 | 0.224 |
IL-17 | |||
d0 | 351.29 ± 55.29 | 386.64 ± 61.88 | 0.768 |
d2 | 406.68 ± 68.21 | 677.80 ± 133.07 | 0.171 |
d7 | 226.20 ± 18.37 | 429.94 ± 11.90 | 0.042 |
FoxP3 | |||
d0 | 430.38 ± 48.95 | 384.52 ± 42.19 | 0.408 |
d2 | 468.85 ± 89.81 | 432.97 ± 44.45 | 0.338 |
d7 | 248.68 ± 58.71 | 361.01 ± 46.75 | 0.109 |
IFN-γ/IL-4 ratio | |||
d0 | 0.44 ± 0.03 | 0.39 ± 0.04 | 0.883 |
d2 | 0.80 ± 0.10 | 0.58 ± 0.03 | 0.198 |
d7 | 1.14 ± 0.08 | 0.56 ± 0.01 | 0.003 |
Table 5 Plasma interferon-γ, interleukin-4, interleukin-17, interleukin-10, transforming growth factor-β1 concentrations between G + E and G groups
Variables | G + E group (pg/mL) | G group (pg/mL) | P |
IFN-γ | |||
d0 | 7.56 ± 0.44 | 6.67 ± 0.70 | 0.653 |
d2 | 11.17 ± 0.97 | 19.94 ± 1.37 | 0.018 |
d7 | 8.67 ± 0.74 | 5.76 ± 0.53 | 0.165 |
IL-4 | |||
d0 | 10.31 ± 1.78 | 10.53 ± 1.28 | 0.892 |
d2 | 21.11 ± 3.76 | 36.69 ± 6.97 | 0.013 |
d7 | 13.00 ± 1.88 | 25.50 ± 2.98 | 0.065 |
IL-17 | |||
d0 | 20.26 ± 5.82 | 18.83 ± 3.95 | 0.304 |
d2 | 27.26 ± 10.30 | 40.10 ± 10.56 | 0.239 |
d7 | 9.12 ± 1.67 | 16.66 ± 2.38 | 0.009 |
IL-10 | |||
d0 | 3.67 ± 0.35 | 3.37 ± 0.31 | 0.528 |
d2 | 7.17 ± 0.86 | 5.97 ± 0.48 | 0.218 |
d7 | 4.09 ± 0.29 | 5.65 ± 0.72 | 0.06 |
TGF-β1 | |||
d0 | 6565 ± 1667 | 5312 ± 1102 | 0.539 |
d2 | 15680 ± 4254 | 8375 ± 1395 | 0.12 |
d7 | 7555 ± 1555 | 10691 ± 2571 | 0.311 |
IFN-γ/ IL-4 | |||
d0 | 0.74 ± 0.10 | 0.65 ± 0.13 | 0.618 |
d2 | 0.67 ± 0.08 | 0.56 ± 0.05 | 0.309 |
d7 | 1.10 ± 0.14 | 0.35 ± 0.08 | < 0.001 |
- Citation: Zhou D, Gu FM, Gao Q, Li QL, Zhou J, Miao CH. Effects of anesthetic methods on preserving anti-tumor T-helper polarization following hepatectomy. World J Gastroenterol 2012; 18(24): 3089-3098
- URL: https://www.wjgnet.com/1007-9327/full/v18/i24/3089.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i24.3089